Radiofrequency ablation highly effective in treating kidney tumors

August 03, 2007

A relatively new, minimally invasive treatment was 93 percent successful in eradicating malignant kidney tumors, according to a recent study conducted by researchers from Wake Forest University Baptist Medical Center in Winston-Salem, NC.

"I have performed many radiofrequency ablations of renal tumors and the results looked promising," said Ronald J. Zagoria, MD, lead author of the study. "I wanted to scientifically review the data to better assess the results and look for patterns that might predict success or complications," he said.

The study consisted of 104 patients with a total of 125 tumors ranging from 0.6 cm to 8.8 cm. In all patients, a biopsy confirmed the presence of renal cell carcinoma (RCC), the most common type of kidney cancer. Of the 125 tumors, 95 were smaller than 3.7 cm and were completely eradicated in one treatment. Fourteen larger tumors were also eradicated after one treatment. Of the 16 remaining larger tumors, seven were eradicated after a second treatment.

"Patients who are not good operative candidates, usually due to co-existing illnesses, and those with multiple renal tumors, now have an excellent option for curing their tumors," said Dr. Zagoria. "Surgery should be the first option, since the long-term results of this procedure have not been substantiated," he said.

"There was a very low rate of serious complications and ablation was uniform and complete throughout the treated area, with no evidence of recurrence within the margins of the treated tumors," said Dr. Zagoria. "Also, ninety-five percent of patients were treated with minimal discomfort and they were able to go home the same day the procedure was completed," he said.
The full results of this study appear in the August issue of the American Journal of Roentgenology, published by the American Roentgen Ray Society.

For Immediate Release Contact:
Necoya Lightsey, 703-858-4304,
Keri Sperry, 703-858-4306,

American College of Radiology

Related Tumors Articles from Brightsurf:

A viable vaccine for tough tumors
While immunotherapies work well for some cancers, others are immune-resistant and condemn patients to the severe side effects of long-term chemo treatment.

Women could conceive after ovarian tumors
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.

Attacking tumors from the inside
A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.

A solid vaccine for liquid tumors
Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years.

Evolutionarily novel genes work in tumors
A team of scientists from Peter the Great St. Petersburg Polytechnic University studied the evolutionary ages of human genes and identified a new class of them expressed in tumors -- tumor specifically expressed, evolutionarily novel (TSEEN) genes.

Identification of all types of germ cells tumors
Germ cell tumors were considered very heterogeneous and diverse, until recently.

Laser light detects tumors
A team of researchers from Jena presents a groundbreaking new method for the rapid, gentle and reliable detection of tumors with laser light.

Better prognosticating for dogs with mammary tumors
For dogs with mammary tumors, deciding a course of treatment can depend on a variety of factors, some of which may seem to contradict one another.

The evolution of brain tumors
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas.

Read More: Tumors News and Tumors Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to